Metal-Based Drugs [98] G. Porzio, P. Marchetti, I. Paris, F. Narducci, E. Ricevuto, and C. Ficorella, “Hypersensitivity reaction to carboplatin: suc- cessful resolution by replacement with cisplatin,” European Journal of Gynaecological Oncology, vol. 23, no. 4, pp. 335– 336, 2002. [99] M. J. Kandel, A. Loehr, P. Harter, A. Traut, K. Gnauert, and A. Du Bois, “Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity,” International Journal of Gynecological Cancer, vol. 15, no. 5, pp. 780–784, 2005. [100] K. T. Elligers, M. Davies, D. Sanchis, T. Ferencz, and M. W. Saif, “Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting?” Journal of the Pancreas, vol. 9, no. 2, pp. 197–202, 2008. [101] A. Ottaiano, R. Tambaro, S. Greggi et al., “Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma,” Anticancer Research, vol. 23, no. 4, pp. 3465–3468, 2003. [102] J. B. Robinson, D. Singh, D. C. Bodurka-Bevers, J. T. Wharton, D. M. Gershenson, and J. K. Wolf, “Hypersen- sitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies,” Gynecologic Oncology, vol. 82, no. 3, pp. 550–558, 2001. [103] M. Markman, K. Zanotti, G. Peterson, B. Kulp, K. Webster, and J. Belinson, “Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity,” Journal of Clinical Oncology, vol. 21, no. 24, pp. 4611–4614, 2003. [104] V. Leguy-Seguin, G. Jolimoy, B. Coudert et al., “Diagnostic and predictive value of skin testing in platinum salt hyper- sensitivity,” Journal of Allergy and Clinical Immunology, vol. 119, no. 3, pp. 726–730, 2007. [105] E. Syrigou, N. Makrilia, A. Vassias et al., “Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?” Anti-Cancer Drugs, vol. 21, no. 3, pp. 333–338, 2010. [106] A. Gowda, R. Goel, J. Berdzik, C. G. Leichman, and M. Javle, “Hypersensitivity reactions to oxaliplatin: incidence and management,” Oncology, vol. 18, no. 13, pp. 1671–1675, 2004. [107] G. Brandi, M. A. Pantaleo, C. Galli et al., “Hypersensitivity reactions related to oxaliplatin (OHP),” British Journal of Cancer, vol. 89, no. 3, pp. 477–481, 2003. [108] P. Bhargava, D. Gammon, and M. J. McCormick, “Hyper- sensitivity and idiosyncratic reactions to oxaliplatin,” Cancer, vol. 100, no. 1, pp. 211–212, 2004. [109] S. W. K. Siu, R. T. T. Chan, and G. K. H. Au, “Hypersensitivity reactions to oxaliplatin: experience in a single institute,” Annals of Oncology, vol. 17, no. 2, pp. 259–261, 2006. [110] L. Meyer, T. Zuberbier, M. Worm, H. Oettle, and H. Riess, “Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule,” Journal of Clinical Oncology, vol. 20, no. 4, pp. 1146–1147, 2002. [111] F. Le´vi, R. Zidani, and J.-L. Misset, “Randomised multicentre trial of chronotherapy with oxaliplatin, ﬂuorouracil, and folinic acid in metastatic colorectal cancer,” Lancet, vol. 350, no. 9079, pp. 681–686, 1997. [112] C. Garuﬁ, A. Cristaudo, B. Vanni et al., “Skin testing and hypersensitivity reactions to oxaliplatin,” Annals of Oncology, vol. 14, no. 3, pp. 497–498, 2003. 11